1-10 of 10
Guenther Gastl
Close
Sort by
Journal Articles

AOP2014, a Novel Peg-Proline-Interferon Alpha-2b with Improved Pharmacokinetic Properties, Is Safe and Well Tolerated and Shows Promising Efficacy in Patients with Polycythemia Vera (PV)

Heinz Gisslinger, MD, PhD, Robert Kralovics, Bettina Gisslinger, Daniel Lechner, MD, Veronika Buxhofer-Ausch, MD, Karin Strecker, MD, Guenther Gastl, MD, Ella Willenbacher, MD, Richard Greil, MD, Alexander Egle, MD, Thomas Melchardt, MD, Sonja Burgstaller, MD, Ernst Schloegl, MD, Franz-Josef Tarmann, MSc, Michael Zoerer, PhD, Christoph Klade, PhD, Oleh Zahriychuk, MD, Josef Thaler, MD
Journal: Blood
Blood (2012) 120 (21): 175.
https://doi.org/10.1182/blood.V120.21.175.175
Published: 2012
Journal Articles

Reinforcement of Cancer Immunotherapy by Adoptive Transfer of Cblb -Deficient Cytotoxic T Lymphocytes Combined with a Dendritic Cell Vaccine

Christina Lutz-Nicoladoni, Patrizia Stoizner, Magdalena Pircher, Stephanie Wallner, Anna Maria Wolf, Guenther Gastl, Josef Penninger, Gottfried Baier, Dominik Wolf
Journal: Blood
Blood (2010) 116 (21): 957.
https://doi.org/10.1182/blood.V116.21.957.957
Published: 2010
Journal Articles

GRP-78 secreted by tumor cells blocks the antiangiogenic activity of bortezomib

Johann Kern, Gerold Untergasser, Christoph Zenzmaier, Bettina Sarg, Guenther Gastl, Eberhard Gunsilius, Michael Steurer
Journal: Blood
Blood (2009) 114 (18): 3960–3967.
https://doi.org/10.1182/blood-2009-03-209668
Published: 2009
Includes: Supplemental data
Journal Articles

CELSG CML 11 “ISTAHIT” Phase III Study – Planned Interim Analysis: High Doses of Imatinib Mesylate (800mg/day) Significantly Improve Rates of Major and Complete Cytogenetic Remissions (MCR, CCR) in Pretreated Ph + /BCR-ABL + CML Patients in Chronic Phase.

Andreas L. Petzer, MD, Dominik Wolf, MD, Dominic Fong, MD, Thomas Lion, MD, Irina Dyagil, MD, Zvenyslava Masliak, MD, Darinka Boskovic, MD, Laimonas Griskevicius, MD, Sandra Lejniece, MD, Stefan Goranov, MD, Liana Gercheva, MD, Aleksandar Stojanovic, MD, Dontcho Peytchev, MD, Nikolay Tzvetkov, MD, Rasa Griniute, MD, Radka Oucheva, MD, Hanno Ulmer, PhD, Marthin Kwakkelstein, MD, Gianluca Fincato, MD, Guenther Gastl, MD
Journal: Blood
Blood (2008) 112 (11): 1112.
https://doi.org/10.1182/blood.V112.11.1112.1112
Published: 2008
Journal Articles

Planned First Efficacy and Safety Analysis of De-Intensified Induction with Fludarabine, Cyclophosphamide Plus Rituximab (FCR) Followed by Fludarabine Plus Rituximab (FR) and Remission Maintenance Therapy with Rituximab in Previously Untreated B-Chronic Lymphocytic Leukemia (B-CLL): The Chairos Study.

Alexander Egle, MD, Lukas Weiss, MD, Gudrun Russ, MD, Ralf Thoedtmann, MD, Lisa Pleyer, MD, Guenther Gastl, MD, Josef Thaler, MD, Andreas Petzer, MD, Inge Tinhofer, PhD, Richard Greil, MD
Journal: Blood
Blood (2007) 110 (11): 2045.
https://doi.org/10.1182/blood.V110.11.2045.2045
Published: 2007
Journal Articles

Retreatment with Alemtuzumab after a First, Successful Alemtuzumab Treatment in B-CLL.

Michael Fiegl, Florian Falkner, Andreas Falkner, Niklas Zojer, Michael Fridrik, Georg Hopfinger, Reinhard Stauder, Ebehard Gunsilius, Johanna Kantner, Martin Erdel, Inge Tinhofer, Guenther Gastl, Richard Greil, the Austrian Cooperation on MabCampath Use in CLL
Journal: Blood
Blood (2007) 110 (11): 4714.
https://doi.org/10.1182/blood.V110.11.4714.4714
Published: 2007
Journal Articles

Alemtuzumab in B-Cell Prolymphoytic Leukemia (B-PLL) and Richter’s Transformation.

Michael Fiegl, Andreas Falkner, Michael Fidrik, Gerhard Postner, Alois Lang, Niklas Zojar, Guenther Gastl, Richard Greil, for the Austrian Cooperation on MabCampath Use in CLL
Journal: Blood
Blood (2006) 108 (11): 4733.
https://doi.org/10.1182/blood.V108.11.4733.4733
Published: 2006
Journal Articles

Maintenance of Telomere Length in Peripheral Blood CD4 + CD25 + Regulatory T-Cells of Cancer Patients Despite Active Proliferation.

Dominik Wolf, MD, Holger Rumpold, MD, Christian Koppelstaetter, MD, Guenther Gastl, MD, Eberhard Gunsilius, MD, Herbert Tilg, MD, Anna M. Wolf, MD
Journal: Blood
Blood (2005) 106 (11): 3309.
https://doi.org/10.1182/blood.V106.11.3309.3309
Published: 2005
Journal Articles

All-Trans Retinoic Acid and Gemtuzumab Ozogamicin as Adjunct To Salvage Therapy in Primary Refractory Acute Myeloid Leukemia: Results of Consecutive Phase II Studies of the AMLSG.

Richard F. Schlenk, MD, Konstanze Doehner, MD, Martina Kerz, Frank Hartmann, MD, Francesco del Valle, MD, Axel Glasmacher, MD, Hans Pralle, MD, Katharina Goetze, MD, Elisabeth Koller, MD, Guenther Gastl, MD, Hans G. Mergenthaler, MD, Hans Salwender, MD, Heinz Kirchen, MD, Detlef Haase, MD, Stephan Kremers, MD, Christoph Nerl, MD, Matthias Theobald, MD, Axel C. Matzdorff, MD, Arnold Ganser, MD, Hartmut Doehner, MD, for the German-Austrian, AML Study Group (AMLSG)
Journal: Blood
Blood (2005) 106 (11): 1849.
https://doi.org/10.1182/blood.V106.11.1849.1849
Published: 2005
Journal Articles

Cytotoxic Activity of the Proteasome Inhibitor MLN-273 but Not of Bortezomib Is Inhibited by MDR1.

Holger Rumpold, MD, Anna M. Wolf, MD, Gerold Untergasser, PhD, Guenther Gastl, MD, Eberhard Gunsilius, MD, Dominik Wolf, MD
Journal: Blood
Blood (2005) 106 (11): 4467.
https://doi.org/10.1182/blood.V106.11.4467.4467
Published: 2005